Creative Planning - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 365 filers reported holding NEKTAR THERAPEUTICS in Q1 2018. The put-call ratio across all filers is 0.43 and the average weighting 0.3%.

Quarter-by-quarter ownership
Creative Planning ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q2 2019$331,000
-8.8%
9,289
-14.0%
0.00%0.0%
Q1 2019$363,000
+2.3%
10,8070.0%0.00%0.0%
Q4 2018$355,000
-45.9%
10,807
+0.4%
0.00%
-50.0%
Q3 2018$656,000
+51.2%
10,768
+21.2%
0.00%0.0%
Q2 2018$434,000
+4.8%
8,883
+127.9%
0.00%0.0%
Q1 2018$414,000
+10250.0%
3,897
+1819.7%
0.00%
Q2 2017$4,000
-78.9%
203
-88.7%
0.00%
Q1 2017$19,000
+26.7%
1,803
-14.3%
0.00%
Q4 2016$15,000
-28.6%
2,103
+75.0%
0.00%
Q3 2016$21,000
+162.5%
1,202
+118.5%
0.00%
Q2 2016$8,000
-98.6%
550
-98.6%
0.00%
-100.0%
Q1 2016$559,000
-16.1%
40,650
+2.8%
0.00%
-20.0%
Q4 2015$666,000
+38.5%
39,550
-9.8%
0.01%
+25.0%
Q3 2015$481,000
-11.7%
43,850
+0.7%
0.00%
-20.0%
Q2 2015$545,000
+21.1%
43,550
+6.5%
0.01%
+25.0%
Q1 2015$450,000
-48.6%
40,900
-27.6%
0.00%
-55.6%
Q4 2014$876,000
+26.2%
56,500
-1.7%
0.01%
+12.5%
Q3 2014$694,000
+14.0%
57,500
+21.1%
0.01%0.0%
Q2 2014$609,000
+5.2%
47,500
-0.5%
0.01%
-11.1%
Q1 2014$579,000
+7.2%
47,750
+0.4%
0.01%0.0%
Q4 2013$540,000
-8.6%
47,550
-15.9%
0.01%
-25.0%
Q3 2013$591,000
-11.3%
56,550
-2.0%
0.01%
-20.0%
Q2 2013$666,00057,7000.02%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q1 2018
NameSharesValueWeighting ↓
TIRSCHWELL & LOEWY INC 588,908$7,138,0001.23%
Granahan Investment Management 3,693,956$44,771,0001.21%
NEA Management Company, LLC 1,825,600$22,126,0001.09%
FIC CAPITAL INC 150,868$1,829,0000.75%
Rhenman & Partners Asset Management AB 181,797$2,203,0000.66%
SOPHROSYNE CAPITAL LLC 60,200$728,0000.64%
HARVEY CAPITAL MANAGEMENT INC 130,400$1,580,0000.63%
Artal Group S.A. 1,300,000$15,756,0000.57%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 564,418$6,840,0000.47%
OppenheimerFunds, Inc. 24,400,000$295,728,0000.35%
View complete list of NEKTAR THERAPEUTICS shareholders